NASDAQ:WINT Windtree Therapeutics (WINT) Stock Price, News & Analysis $0.0003 0.00 (-70.00%) As of 03:31 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesNews and TrendsSEC Filings About Windtree Therapeutics Stock (NASDAQ:WINT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Windtree Therapeutics alerts:Sign Up Key Stats Today's Range$0.0003▼$0.000350-Day Range N/A52-Week Range$0.00▼$0.13Volume88,928 shsAverage Volume224,895 shsMarket Capitalization$13.50 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Windtree Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for cardiovascular diseases and other serious medical conditions. The company’s lead product candidate is istaroxime, an investigational therapy designed to improve cardiac contractility and diastolic function through mechanisms involving the SERCA2a calcium pump and the sodium-potassium ATPase. Windtree has been evaluating istaroxime in clinical studies for acute decompensated heart failure and cardiogenic shock, including patients with heart failure with reduced ejection fraction. The company’s development efforts are intended to address conditions in which the heart cannot pump sufficient blood to meet the body’s needs. The company also maintains research and development programs in oncology and other therapeutic areas. Windtree was formerly known as Discovery Laboratories and adopted its current name following a strategic combination with CVie Therapeutics, which brought istaroxime into its portfolio. The company is headquartered in Warrington, Pennsylvania, and conducts development activities through clinical and research programs aimed at advancing its investigational medicines.AI Generated. May Contain Errors. Read More Receive WINT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Windtree Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. WINT Stock News HeadlinesTransCode Therapeutics Announces Leadership TransitionSeptember 10, 2026 | prnewswire.comWindtree Therapeutics Delays Filing of Annual ReportApril 1, 2026 | tipranks.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.October 22 at 1:00 AM | Profits Run (Ad)CommLoan Achieves Nationwide Regulatory Approval Across All 50 StatesMarch 17, 2026 | prnewswire.comWindtree Therapeutics Announces Sudden Departure of President and COOJanuary 17, 2026 | theglobeandmail.comWindtree sells heart drug assets, keeps a cut of any future breakthroughDecember 30, 2025 | msn.comWindtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug CandidatesDecember 23, 2025 | finance.yahoo.comWindtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech SpaceDecember 4, 2025 | markets.businessinsider.comSee More Headlines WINT Stock Analysis - Frequently Asked Questions How have WINT shares performed this year? Windtree Therapeutics' stock was trading at $0.0320 on January 1st, 2026. Since then, WINT stock has decreased by 99.1% and is now trading at $0.0003. How were Windtree Therapeutics' earnings last quarter? Windtree Therapeutics, Inc. (NASDAQ:WINT) announced its quarterly earnings results on Tuesday, August, 19th. The company reported ($3.06) earnings per share for the quarter, beating analysts' consensus estimates of ($99.00) by $95.94. When did Windtree Therapeutics' stock split? Windtree Therapeutics's stock reverse split on Friday, February 21st 2025.The 1-50 reverse split was announced on Tuesday, February 18th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Windtree Therapeutics? Shares of WINT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Windtree Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Windtree Therapeutics investors own include Tonix Pharmaceuticals (TNXP), Novavax (NVAX), Palantir Technologies (PLTR), Plus Therapeutics (PSTV), Advanced Micro Devices (AMD), Globalstar (GSAT) and Intel (INTC). Company Calendar Last Earnings8/19/2025Today10/22/2026Next Earnings (Estimated)11/26/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:WINT CIK946486 Webwww.windtreetx.com Phone(215) 488-9300Fax215-488-9301Employees30Year Founded1992Profitability EPS (Trailing Twelve Months)($8.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-207.34% Return on Assets-50.19% Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick Ratio0.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book0.00Miscellaneous Outstanding Shares44,988,000Free Float3,656,000Market Cap$13.50 thousand OptionableNot Optionable Beta1.72 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:WINT) was last updated on 10/22/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Windtree Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
